Expertise in
24
conditions

Yasuyuki Suzuki

Tokyo, JP 
Expertise in
24
conditions
Tokyo, JP 

Overview

Yasuyuki Suzuki practices practicing medicine in Tokyo, Japan.

Suzuki is highly rated in 24 conditions, according to our data. Their clinical expertise encompasses Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome), Pancreaticoduodenectomy, and Endoscopy.

They are actively involved in clinical research, co-authoring 476 peer reviewed articles.

Locations

Tokyo, Japan
Other Locations
Hirosaki, Japan
Japan
Kanagawa, Japan
Toon, Japan
Itabashi, 1738610, Japan
Tsukuba, 3058575, Japan
Shinjiku, Japan
Sumoto, 6560021, Japan
Isehara, 2591193, Japan
Gifu-shi, 5011194, Japan
Shinjuku, Japan
Chiyoda, Japan
Toyonaka, 5608531, Japan
Fuji, Japan
Akita, 0110948, Japan
Matsuyama, Japan
Osaka, 5608531, Japan
Ikenobe, 7610793, Japan
Chiyoda, 1018309, Japan
Setagaya, Japan
Kita, Japan
Takamatsu, Japan
Sagamihara, Japan
Atsugi, Japan
Ube, Japan
Miki, 7610793, Japan
Sumida, 1310034, Japan
Tokai, Japan
Sapporo, 0608589, Japan
Kurume, Japan
Hiratsuka, Japan
Kanazawa, Japan
Ami, 3001192, Japan
Aomori, Japan
Inashiki, 3001192, Japan
Inzai, 2701695, Japan
Iwanai, Japan
Uwajima, 7988510, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

476 Total Publications

Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study.
Real-world safety and efficacy of enzalutamide versus darolutamide in nonmetastatic castration-resistant prostate cancer: a multicenter retrospective study.
Journal: ESMO real world data and digital oncology
Published: July 13, 2026

Frequently Asked Questions about Yasuyuki Suzuki

Is Yasuyuki Suzuki a top-rated expert for Mucopolysaccharidoses (MPS)?

MediFind is an objective health platform that identifies experts based on real-world data. Yasuyuki Suzuki is classified as an Distinguished expert for Mucopolysaccharidoses (MPS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yasuyuki Suzuki participate in research or clinical trials?

Yes. Yasuyuki Suzuki has published 476 articles and abstracts on conditions like Mucopolysaccharidoses (MPS). You can view a list of Yasuyuki Suzuki's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Suzuki's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 130 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile